Ongoing Clinical Trials for Asymptomatic HIV Infection
Currently, there is one ongoing clinical trial focused on asymptomatic HIV infection, also known as early-stage HIV-1 infection without symptoms. This trial is investigating the use of dasatinib, a protein kinase inhibitor, to evaluate its safety and tolerability in patients who have recently contracted HIV-1 but do not yet show any symptoms. The study is being conducted in Spain and aims to provide insights into whether this medication can help manage the virus before antiretroviral therapy is needed.
Clinical trial locations
Study on the Safety and Effects of Dasatinib in Patients with Recent HIV-1 Infection
This clinical trial is exploring the safety and tolerability of dasatinib in people who have recently been infected with HIV-1 but remain asymptomatic. The study is being conducted in Spain and represents an important investigation into alternative approaches for managing early HIV infection.
Main inclusion criteria:
- Adults aged between 18 and 65 years
- Documented HIV-1 infection that has been present for more than 3 months without causing any symptoms
- No previous antiretroviral therapy
- CD4 T cell count greater than 350 cells per microliter, which indicates a relatively healthy immune system
- Willingness to provide written informed consent to participate in the study
Main exclusion criteria:
- Showing symptoms of HIV-1 infection
- HIV infection diagnosed less than 3 months ago
- Currently taking medications that could interfere with the study drug
- History of severe allergic reactions to similar medications
- Significant heart problems or uncontrolled high blood pressure
- Active infections other than HIV-1
- Pregnancy or breastfeeding
- Participation in another clinical trial
- History of cancer within the past 5 years
Focus and goal of the trial: The primary objective of this study is to evaluate how safe and well-tolerated dasatinib is when used as a treatment option for people with recent HIV-1 infection who do not yet show symptoms. Participants will take dasatinib orally for a period of 4 weeks as a single therapy. During this time, researchers will closely monitor their health, looking for any side effects or adverse reactions. The study will also examine how the medication affects the immune system, including the number of certain immune cells and markers of inflammation, as well as measuring the amount of virus present in the body before any other antiretroviral therapy is started. The trial is expected to continue until 2026, allowing researchers to collect comprehensive information over time about whether dasatinib could be a viable treatment option for this patient population.
Investigational drug: The medication being tested is dasatinib, a type of immunomodulatory tyrosine kinase inhibitor. This drug works by blocking certain proteins that are involved in helping the virus replicate and grow in the body. By inhibiting these proteins, dasatinib may slow down the progression of the infection and help preserve immune function in people with recent HIV-1 infection. The medication is administered orally in tablet form, making it convenient for patients to take.
Summary
Currently, only one clinical trial is actively investigating new treatment approaches for asymptomatic HIV infection. This trial is being conducted in Spain and focuses specifically on dasatinib, a protein kinase inhibitor that has shown promise in blocking viral replication. The study targets a particular group of patients: those who have been infected with HIV-1 for more than 3 months but have not yet developed symptoms and have not started antiretroviral therapy. The trial represents an important step in understanding whether medications like dasatinib could offer benefits in the early stages of HIV infection, potentially helping to preserve immune function before traditional antiretroviral therapy becomes necessary. The limited number of trials in this specific area highlights the ongoing need for research into treatment options for people in the asymptomatic phase of HIV infection.
